ruxolitinib
Jakafi Approved To Treat Chronic GVHD in Adults and Children
The FDA approved ruxolitinib (Jakafi, Incyte) for chronic graft-versus-host disease after failure of one or two ...
OCTOBER 14, 2021
Oral JAK Inhibitor Shows Efficacy for Steroid-Refractory Graft-Versus-Host Disease
The oral JAK inhibitor ruxolitinib is associated with significant clinical improvement in patients with ...
JANUARY 26, 2021
Ruxolitinib + Capecitabine Improves ORR But Not PFS or OS in HER2- Breast Ca With Elevated CRP
In patients with advanced HER2-negative breast cancer with elevated C-reactive protein (CRP) levels, adding ...
APRIL 28, 2017
Load more